Tolmar
Private Company
Funding information not available
Overview
Tolmar is a private, commercial-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of long-acting injectable drugs. Founded in 2002, it has built a portfolio of approved products sold in over 89 countries, primarily in therapeutic areas like prostate cancer, central precocious puberty, and testosterone replacement therapy. The company operates with a fully integrated model, controlling R&D, manufacturing in Colorado, and sales, which allows for a direct path to market and reliable supply. With over 1,100 employees, Tolmar leverages over 30 years of experience in long-acting injectables to differentiate itself and pursue partnerships for further growth.
Technology Platform
Specialized expertise in the development and manufacturing of long-acting injectable (LAI) drug formulations, with over 30 years of experience. Platform includes integrated R&D, proprietary manufacturing processes, and synchronized commercialization capabilities (TOLMARsync).
Opportunities
Risk Factors
Competitive Landscape
Tolmar competes with large pharmaceutical companies that market their own long-acting injectables (e.g., AbbVie, Pfizer, Endo) as well as other specialty pharma and generic drug manufacturers focused on complex formulations. Its key differentiators are its fully integrated model, deep expertise in LAI technology, and dedicated focus on the patient and clinician experience with injectable therapies.